We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
It may be time to simplify the FDA’s many expedited review programs, according to a Harvard research team that studied the agency’s drug reviews over the past four decades. Read More
Eli Lilly plans to launch two new cheaper insulin products amid criticism about the availability of its lower-cost insulins on pharmacy shelves. Read More
The U.S. Supreme Court this week opted not to take up a patent suit between Vanda Pharmaceuticals and generic drugmaker Hikma Pharmaceuticals over Vanda’s schizophrenia treatment Fanapt (iloperidone). Read More
Republicans on the House Energy and Commerce Committee on Tuesday revived their investigation into the role three drugmakers played in the opioid crisis, pressing Insys, Mallinckrodt and Purdue Pharma for more details. Read More